A phase 1/2 trial of Zinc-64 Aspartate in advanced solid tumours, run by Vector Vitale LLC, now recruiting.
Safety and Efficacy of KLS-1 Monotherapy in Malignant Neoplasms is a phase 1/2 interventional study registered as NCT06506643 by Vector Vitale LLC, with 36 participants planned, started 2024-05-15 and due to reach its primary completion in 2028-12-31. Interventions recorded: Zinc-64 Aspartate.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.